Pharmacokinetics Services Market Analysis, Size, Share, Growth, Trends, and Forecast by 2031

The pharmacokinetics services market size is projected to reach US$ 874.96 million by 2031 from US$ 1,579.87 million in 2023. The market is expected to register a CAGR of 7.6% in 2023–2031. The increasing adoption of Big Data analytics is likely to remain a key pharmacokinetics services market trend.

Pharmacokinetics Services Market Analysis

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level and no-observed effect level (NOEL); these studies also involve conducting pharmacokinetic/pharmacodynamic testing. The main focus of any preclinical program conducted is to support the analysis of a safe and effective dose range. Several toxicology studies provide data on the NOEL, i.e., the highest dose at which a drug exhibits no adverse effects. This dose level is further converted to an HED level on the basis of a comparative body-surface area if there is a lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role in propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted to hospitals. The pharmacokinetic model is often applied to determine exposure to drugs and concentrations of drugs to analyze optimal dosage and the disposition of drugs in the human body. Healthcare providers implement the principles of pharmacokinetic studies to monitor drug concentrations, determine doses of some drugs, maximize the intended therapeutic outcomes, and minimize toxicities. Thus, the expanding range of applications of pharmacokinetic studies bolsters the pharmacokinetics services market growth.

Pharmacokinetics Services Market Overview

The rising prevalence of chronic and infectious diseases, expanding application of pharmacokinetic studies, and outsourcing of pharmacokinetics services to contract research organizations boost the growth of the pharmacokinetics services market. According to the World Health Organization’s (WHO) 2024 data, ~422 million people in the world suffer from diabetes, and middle- and low-income countries account for most of these cases, causing approximately 1.5 million deaths every year. Pharmacokinetic studies are essential for understanding how drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Pharmacokinetics Services Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Pharmacokinetics Services Market Drivers and Opportunities

Rising Prevalence of Chronic and Infectious Diseases Propel Market Growth

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization’s (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics to Drive Market in Coming Years

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions (i.e., pharmacokinetic/pharmacodynamic predictions) at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess biopharmaceutical properties to analyze the bioavailability of drugs and determine their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.

Pharmacokinetics Services Market Share Analysis by Geography

The geographic scope of the pharmacokinetics services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. In North America, the pharmacokinetics services market is currently in the growth phase and experiencing exponential growth. The US accounts for the largest share of the pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021. The rising number of research studies and clinical trials in North American countries is expected to have a positive impact on the pharmacokinetics services market in this region.

Pharmacokinetics Services Market Regional Insights

The regional trends and factors influencing the Pharmacokinetics Services Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Pharmacokinetics Services Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Pharmacokinetics Services Market Report Scope

Pharmacokinetics Services Market Players Density: Understanding Its Impact on Business Dynamics

The Pharmacokinetics Services Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Pharmacokinetics Services Market are:

1. Charles River Laboratories International Inc.,
2. Eurofins Scientific SE,
3. Evotec SE,
4. Certara Inc.,
5. Parexel International Corp,
6. Thermo Fisher Scientific Inc.,

Disclaimer: The companies listed above are not ranked in any particular order.

Pharmacokinetics Services Market News and Recent Developments

The pharmacokinetics services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the pharmacokinetics services market are mentioned below:

• Thermo Fisher Scientific expanded its clinical research operations with the opening of a state-of-the-art bioanalytical lab in Richmond, Virginia. The new unit will support the burgeoning demand generated in the biopharmaceutical ecosystem for consistent, high-quality laboratory services to accelerate drug development. The Richmond Bioanalytical Lab, whose entities have been operating since 1985, provides services for all phases of small molecule drug, biologics, vaccine, and biomarker development. Drug testing services include drug PK/PD, and immunogenicity and biomarker quantitation to support drug efficacy and safety. (Source: Thermo Fisher Scientific, Press Release, October 2022)
• Charles River Laboratories International, Inc., partnered with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Kibur’s microdevice technology can hold up to 20 different compounds for local administration, which allows it to dose therapies directly into disease tissue, allowing for investigative studies of early-stage compounds where pharmacokinetic properties are poorly understood. (Source: Charles River Laboratories International, Inc., Newsletter, February 2021)

Pharmacokinetics Services Market Report Coverage and Deliverables

The “Pharmacokinetics Services Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:

• Pharmacokinetics services market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Pharmacokinetics services market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Pharmacokinetics services market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmacokinetics services market
• Detailed company profiles